1. U.S. Food and Drug Administration. FDA guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics, 〈http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf〉; May, 2007 [accessed June 6, 2011].
2. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009
3. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group;Scher;J Clin Oncol,2008
4. U.S. Food and Drug Administration. FDA public workshop on clinical trial endpoints in prostate cancer, 〈http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/CancerDrugs/ucm094586.htm〉; June 21–22, 2004 [accessed June 6, 2011].
5. Prostate cancer in the late 1990s: hormone refractory disease options;Moul;Urol Nurs,1999